Molibresib

N/A

Report date: 2025/04/30 20:00:42
NME

Base Information

Drug NameMolibresib
Drug Alias NameGSK-525762AGSK-525762CGSK-525762IBET-762
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBromodomain and extra terminal domain protein inhibitors
TargetsBromodomain and extra terminal domain protein
Therapy Area/IndicationsSolid tumoursPancreatic NeoplasmsLymphoma, T-Cell +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesNetherlands +[8] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline PlcNational Cancer Institute
Active IndicationsN/A
Inactive IndicationsSolid tumoursPancreatic NeoplasmsLymphoma, T-Cell +[7] 

Other Information

ATC CodeN/A
Related LinksN/A